KR20170102002A - 에볼라 바이러스 백신접종을 위한 방법 및 조성물 - Google Patents
에볼라 바이러스 백신접종을 위한 방법 및 조성물 Download PDFInfo
- Publication number
- KR20170102002A KR20170102002A KR1020177022208A KR20177022208A KR20170102002A KR 20170102002 A KR20170102002 A KR 20170102002A KR 1020177022208 A KR1020177022208 A KR 1020177022208A KR 20177022208 A KR20177022208 A KR 20177022208A KR 20170102002 A KR20170102002 A KR 20170102002A
- Authority
- KR
- South Korea
- Prior art keywords
- vector
- ebola virus
- virus antigen
- seq
- immune response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241001115402 Ebolavirus Species 0.000 title claims abstract description 210
- 238000000034 method Methods 0.000 title claims abstract description 199
- 239000000203 mixture Substances 0.000 title claims description 202
- 238000002255 vaccination Methods 0.000 title abstract description 24
- 239000013598 vector Substances 0.000 claims abstract description 539
- 108091007433 antigens Proteins 0.000 claims abstract description 376
- 102000036639 antigens Human genes 0.000 claims abstract description 376
- 239000000427 antigen Substances 0.000 claims abstract description 374
- 230000028993 immune response Effects 0.000 claims abstract description 167
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 151
- 230000036039 immunity Effects 0.000 claims abstract description 41
- 241001135569 Human adenovirus 5 Species 0.000 claims description 269
- 210000004027 cell Anatomy 0.000 claims description 224
- 108090000623 proteins and genes Proteins 0.000 claims description 215
- 238000012217 deletion Methods 0.000 claims description 142
- 230000037430 deletion Effects 0.000 claims description 142
- 230000010076 replication Effects 0.000 claims description 129
- 230000002950 deficient Effects 0.000 claims description 111
- 102000004169 proteins and genes Human genes 0.000 claims description 104
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims description 103
- 150000007523 nucleic acids Chemical group 0.000 claims description 84
- 230000014509 gene expression Effects 0.000 claims description 78
- 230000003612 virological effect Effects 0.000 claims description 73
- 241000700605 Viruses Species 0.000 claims description 62
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 61
- 102000039446 nucleic acids Human genes 0.000 claims description 51
- 108020004707 nucleic acids Proteins 0.000 claims description 51
- 230000002163 immunogen Effects 0.000 claims description 50
- 238000011282 treatment Methods 0.000 claims description 49
- 239000002245 particle Substances 0.000 claims description 45
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 43
- 230000024932 T cell mediated immunity Effects 0.000 claims description 37
- 238000009169 immunotherapy Methods 0.000 claims description 37
- 108010002586 Interleukin-7 Proteins 0.000 claims description 31
- 241001115394 Reston ebolavirus Species 0.000 claims description 30
- 241001115376 Sudan ebolavirus Species 0.000 claims description 30
- 210000004443 dendritic cell Anatomy 0.000 claims description 30
- 241000884921 Bundibugyo ebolavirus Species 0.000 claims description 29
- 241000282472 Canis lupus familiaris Species 0.000 claims description 29
- 241001115374 Tai Forest ebolavirus Species 0.000 claims description 29
- 230000001225 therapeutic effect Effects 0.000 claims description 29
- 239000013603 viral vector Substances 0.000 claims description 29
- 230000003472 neutralizing effect Effects 0.000 claims description 28
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 23
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 22
- 230000004048 modification Effects 0.000 claims description 21
- 238000012986 modification Methods 0.000 claims description 21
- -1 IL- 6 Proteins 0.000 claims description 19
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 18
- 108010002350 Interleukin-2 Proteins 0.000 claims description 17
- 102000000588 Interleukin-2 Human genes 0.000 claims description 17
- 230000001939 inductive effect Effects 0.000 claims description 17
- 101150029662 E1 gene Proteins 0.000 claims description 14
- 230000028327 secretion Effects 0.000 claims description 14
- 102000013462 Interleukin-12 Human genes 0.000 claims description 13
- 108010065805 Interleukin-12 Proteins 0.000 claims description 13
- 108091026890 Coding region Proteins 0.000 claims description 12
- 230000008350 antigen-specific antibody response Effects 0.000 claims description 12
- 102000003814 Interleukin-10 Human genes 0.000 claims description 11
- 108090000174 Interleukin-10 Proteins 0.000 claims description 11
- 102000003816 Interleukin-13 Human genes 0.000 claims description 11
- 108090000176 Interleukin-13 Proteins 0.000 claims description 11
- 102000003810 Interleukin-18 Human genes 0.000 claims description 11
- 108090000171 Interleukin-18 Proteins 0.000 claims description 11
- 102000004890 Interleukin-8 Human genes 0.000 claims description 11
- 108090001007 Interleukin-8 Proteins 0.000 claims description 11
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 102000000585 Interleukin-9 Human genes 0.000 claims description 9
- 108010002335 Interleukin-9 Proteins 0.000 claims description 9
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- WEYNBWVKOYCCQT-UHFFFAOYSA-N 1-(3-chloro-4-methylphenyl)-3-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)thio]ethyl}urea Chemical compound O1C(CN(C)C)=CC=C1CSCCNC(=O)NC1=CC=C(C)C(Cl)=C1 WEYNBWVKOYCCQT-UHFFFAOYSA-N 0.000 claims description 6
- 101710137115 Adenylyl cyclase-associated protein 1 Proteins 0.000 claims description 6
- 101150005585 E3 gene Proteins 0.000 claims description 6
- 101150066038 E4 gene Proteins 0.000 claims description 6
- 238000011510 Elispot assay Methods 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 230000000735 allogeneic effect Effects 0.000 claims description 5
- 150000003431 steroids Chemical class 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 208000032843 Hemorrhage Diseases 0.000 claims description 4
- 230000000740 bleeding effect Effects 0.000 claims description 4
- 239000003246 corticosteroid Substances 0.000 claims description 4
- 229960001334 corticosteroids Drugs 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 210000002865 immune cell Anatomy 0.000 claims description 4
- 239000002955 immunomodulating agent Substances 0.000 claims description 4
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 4
- 239000003018 immunosuppressive agent Substances 0.000 claims description 4
- 230000002018 overexpression Effects 0.000 claims description 4
- 230000002441 reversible effect Effects 0.000 claims description 4
- 208000024799 Thyroid disease Diseases 0.000 claims description 3
- 230000006037 cell lysis Effects 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 208000021510 thyroid gland disease Diseases 0.000 claims description 3
- WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical compound FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 2
- 206010019799 Hepatitis viral Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 229930192392 Mitomycin Natural products 0.000 claims description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 210000000601 blood cell Anatomy 0.000 claims description 2
- 229960004117 capecitabine Drugs 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 238000010494 dissociation reaction Methods 0.000 claims description 2
- 230000005593 dissociations Effects 0.000 claims description 2
- 210000002919 epithelial cell Anatomy 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 201000001862 viral hepatitis Diseases 0.000 claims description 2
- 102000000704 Interleukin-7 Human genes 0.000 claims 10
- 102100027241 Adenylyl cyclase-associated protein 1 Human genes 0.000 claims 3
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 206010068319 Oropharyngeal pain Diseases 0.000 claims 1
- 201000007100 Pharyngitis Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 206010062237 Renal impairment Diseases 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 239000003978 infusion fluid Substances 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 230000005977 kidney dysfunction Effects 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 230000005976 liver dysfunction Effects 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 abstract description 116
- 235000018102 proteins Nutrition 0.000 description 93
- 108090000765 processed proteins & peptides Proteins 0.000 description 79
- 102000004196 processed proteins & peptides Human genes 0.000 description 76
- 229920001184 polypeptide Polymers 0.000 description 75
- 102000003886 Glycoproteins Human genes 0.000 description 61
- 108090000288 Glycoproteins Proteins 0.000 description 61
- 102000007999 Nuclear Proteins Human genes 0.000 description 56
- 108010089610 Nuclear Proteins Proteins 0.000 description 56
- 239000012634 fragment Substances 0.000 description 55
- 101150026858 VP30 gene Proteins 0.000 description 52
- 101150036892 VP40 gene Proteins 0.000 description 52
- 101150010086 VP24 gene Proteins 0.000 description 50
- 101150077651 VP35 gene Proteins 0.000 description 50
- 102000040430 polynucleotide Human genes 0.000 description 49
- 108091033319 polynucleotide Proteins 0.000 description 49
- 239000002157 polynucleotide Substances 0.000 description 49
- 238000002649 immunization Methods 0.000 description 44
- 230000003053 immunization Effects 0.000 description 42
- 208000015181 infectious disease Diseases 0.000 description 38
- 230000000694 effects Effects 0.000 description 35
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 34
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 33
- 230000006870 function Effects 0.000 description 31
- 239000000047 product Substances 0.000 description 27
- 230000002829 reductive effect Effects 0.000 description 26
- 210000002845 virion Anatomy 0.000 description 26
- 241000282412 Homo Species 0.000 description 25
- 230000001965 increasing effect Effects 0.000 description 25
- 230000035772 mutation Effects 0.000 description 24
- 230000004044 response Effects 0.000 description 24
- 101710164463 Preterminal protein Proteins 0.000 description 23
- 239000002773 nucleotide Substances 0.000 description 22
- 125000003729 nucleotide group Chemical group 0.000 description 22
- 102100021592 Interleukin-7 Human genes 0.000 description 21
- 239000002585 base Substances 0.000 description 20
- 238000013518 transcription Methods 0.000 description 20
- 230000035897 transcription Effects 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 19
- 241000711408 Murine respirovirus Species 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 17
- 230000005847 immunogenicity Effects 0.000 description 17
- 238000006467 substitution reaction Methods 0.000 description 17
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 15
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 230000004083 survival effect Effects 0.000 description 15
- 108700019146 Transgenes Proteins 0.000 description 14
- 230000004927 fusion Effects 0.000 description 14
- 230000008088 immune pathway Effects 0.000 description 14
- 239000003607 modifier Substances 0.000 description 14
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 13
- 108010067390 Viral Proteins Proteins 0.000 description 13
- 230000001900 immune effect Effects 0.000 description 13
- 230000037361 pathway Effects 0.000 description 13
- 238000013459 approach Methods 0.000 description 12
- 230000035800 maturation Effects 0.000 description 12
- 230000001177 retroviral effect Effects 0.000 description 12
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 11
- 238000011220 combination immunotherapy Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 10
- 238000004806 packaging method and process Methods 0.000 description 10
- 230000003389 potentiating effect Effects 0.000 description 10
- 230000008685 targeting Effects 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 229940124722 Ebola vaccine Drugs 0.000 description 9
- 102000000646 Interleukin-3 Human genes 0.000 description 9
- 108010002386 Interleukin-3 Proteins 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 9
- 101710172711 Structural protein Proteins 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 9
- 239000000835 fiber Substances 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000003780 insertion Methods 0.000 description 9
- 230000037431 insertion Effects 0.000 description 9
- 108090000565 Capsid Proteins Proteins 0.000 description 8
- 102100023321 Ceruloplasmin Human genes 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 8
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 8
- 108091008874 T cell receptors Proteins 0.000 description 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 8
- 102100040247 Tumor necrosis factor Human genes 0.000 description 8
- 210000000234 capsid Anatomy 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 230000004853 protein function Effects 0.000 description 8
- 229940021747 therapeutic vaccine Drugs 0.000 description 8
- 238000010361 transduction Methods 0.000 description 8
- 230000026683 transduction Effects 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 7
- 241000701022 Cytomegalovirus Species 0.000 description 7
- 230000004543 DNA replication Effects 0.000 description 7
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 7
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 7
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 241000713666 Lentivirus Species 0.000 description 7
- 230000005867 T cell response Effects 0.000 description 7
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 7
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 7
- 230000004888 barrier function Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 229940001442 combination vaccine Drugs 0.000 description 7
- 230000005746 immune checkpoint blockade Effects 0.000 description 7
- 230000001506 immunosuppresive effect Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- 102100038078 CD276 antigen Human genes 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 101710155188 Hexon-interlacing protein Proteins 0.000 description 6
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 6
- 102000017578 LAG3 Human genes 0.000 description 6
- 230000006044 T cell activation Effects 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 238000012384 transportation and delivery Methods 0.000 description 6
- 229940023835 Ad-based vaccine Drugs 0.000 description 5
- 101150013553 CD40 gene Proteins 0.000 description 5
- 206010061818 Disease progression Diseases 0.000 description 5
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 5
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 5
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 5
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000005750 disease progression Effects 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 238000001476 gene delivery Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 241001430294 unidentified retrovirus Species 0.000 description 5
- 229940126580 vector vaccine Drugs 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 101710185679 CD276 antigen Proteins 0.000 description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 description 4
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 241000450599 DNA viruses Species 0.000 description 4
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 4
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 108060004795 Methyltransferase Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 4
- 101710188053 Protein D Proteins 0.000 description 4
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- 101710132893 Resolvase Proteins 0.000 description 4
- 108020005202 Viral DNA Proteins 0.000 description 4
- 108700005077 Viral Genes Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 229940027570 adenoviral vector vaccine Drugs 0.000 description 4
- 229940021704 adenovirus vaccine Drugs 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000004186 co-expression Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 230000015788 innate immune response Effects 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000003584 silencer Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 108010029697 CD40 Ligand Proteins 0.000 description 3
- 102100032937 CD40 ligand Human genes 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108700039887 Essential Genes Proteins 0.000 description 3
- 102100029951 Estrogen receptor beta Human genes 0.000 description 3
- 101710145505 Fiber protein Proteins 0.000 description 3
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 description 3
- 101710192606 Latent membrane protein 2 Proteins 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 102100033082 TNF receptor-associated factor 3 Human genes 0.000 description 3
- 101710109576 Terminal protein Proteins 0.000 description 3
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 3
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000005809 anti-tumor immunity Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 229910052804 chromium Inorganic materials 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 230000001024 immunotherapeutic effect Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 239000013638 trimer Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- 208000010370 Adenoviridae Infections Diseases 0.000 description 2
- 101150051188 Adora2a gene Proteins 0.000 description 2
- 108700023418 Amidases Proteins 0.000 description 2
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 102100025221 CD70 antigen Human genes 0.000 description 2
- 102100035793 CD83 antigen Human genes 0.000 description 2
- 101710198223 Capsid fiber protein Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 2
- 101710121417 Envelope glycoprotein Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 108091008794 FGF receptors Proteins 0.000 description 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102100031351 Galectin-9 Human genes 0.000 description 2
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 description 2
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 2
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 2
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 2
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 2
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 2
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 description 2
- 102100034980 ICOS ligand Human genes 0.000 description 2
- 101150032643 IVa2 gene Proteins 0.000 description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 102100022297 Integrin alpha-X Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108010043610 KIR Receptors Proteins 0.000 description 2
- 101150062031 L gene Proteins 0.000 description 2
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102100034256 Mucin-1 Human genes 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 102000004473 OX40 Ligand Human genes 0.000 description 2
- 108010042215 OX40 Ligand Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 101710194807 Protective antigen Proteins 0.000 description 2
- 101710149951 Protein Tat Proteins 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 102000004389 Ribonucleoproteins Human genes 0.000 description 2
- 108010081734 Ribonucleoproteins Proteins 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 101710165474 Tumor necrosis factor receptor superfamily member 5 Proteins 0.000 description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 2
- 102000016540 Tyrosine aminotransferases Human genes 0.000 description 2
- 108010042606 Tyrosine transaminase Proteins 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 108010087302 Viral Structural Proteins Proteins 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 102000005922 amidase Human genes 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003263 anti-adenoviral effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000002141 anti-parasite Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 239000003096 antiparasitic agent Substances 0.000 description 2
- 230000005975 antitumor immune response Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004900 c-terminal fragment Anatomy 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 229940126546 immune checkpoint molecule Drugs 0.000 description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004779 membrane envelope Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 210000004296 naive t lymphocyte Anatomy 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 229940021993 prophylactic vaccine Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 231100000440 toxicity profile Toxicity 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000017613 viral reproduction Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
- 102100035990 Adenosine receptor A2a Human genes 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000701802 Aviadenovirus Species 0.000 description 1
- 102100022970 Basic leucine zipper transcriptional factor ATF-like Human genes 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 description 1
- 108700016947 Bos taurus structural-GP Proteins 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101150104396 C7 gene Proteins 0.000 description 1
- 102100024263 CD160 antigen Human genes 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 102100029761 Cadherin-5 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100026549 Caspase-10 Human genes 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100038918 Caspase-6 Human genes 0.000 description 1
- 102100038902 Caspase-7 Human genes 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 description 1
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 description 1
- 108010037897 DC-specific ICAM-3 grabbing nonintegrin Proteins 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 102400000686 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- 102100026693 FAS-associated death domain protein Human genes 0.000 description 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 1
- 101150117028 GP gene Proteins 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 102100040754 Guanylate cyclase soluble subunit alpha-1 Human genes 0.000 description 1
- 102100040735 Guanylate cyclase soluble subunit alpha-2 Human genes 0.000 description 1
- 102100040739 Guanylate cyclase soluble subunit beta-1 Human genes 0.000 description 1
- 102100028963 Guanylate cyclase soluble subunit beta-2 Human genes 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 101150046249 Havcr2 gene Proteins 0.000 description 1
- 102100039165 Heat shock protein beta-1 Human genes 0.000 description 1
- 101710100504 Heat shock protein beta-1 Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 1
- 102100028008 Heme oxygenase 2 Human genes 0.000 description 1
- 208000032982 Hemorrhagic Fever with Renal Syndrome Diseases 0.000 description 1
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 102100029235 Histone-lysine N-methyltransferase NSD3 Human genes 0.000 description 1
- 102100035081 Homeobox protein TGIF1 Human genes 0.000 description 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 1
- 101000783751 Homo sapiens Adenosine receptor A2a Proteins 0.000 description 1
- 101000903742 Homo sapiens Basic leucine zipper transcriptional factor ATF-like Proteins 0.000 description 1
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101000983518 Homo sapiens Caspase-10 Proteins 0.000 description 1
- 101000741087 Homo sapiens Caspase-6 Proteins 0.000 description 1
- 101000741014 Homo sapiens Caspase-7 Proteins 0.000 description 1
- 101000983528 Homo sapiens Caspase-8 Proteins 0.000 description 1
- 101000943420 Homo sapiens Cytokine-inducible SH2-containing protein Proteins 0.000 description 1
- 101001010910 Homo sapiens Estrogen receptor beta Proteins 0.000 description 1
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
- 101001038755 Homo sapiens Guanylate cyclase soluble subunit alpha-1 Proteins 0.000 description 1
- 101001038749 Homo sapiens Guanylate cyclase soluble subunit alpha-2 Proteins 0.000 description 1
- 101001038731 Homo sapiens Guanylate cyclase soluble subunit beta-1 Proteins 0.000 description 1
- 101001059095 Homo sapiens Guanylate cyclase soluble subunit beta-2 Proteins 0.000 description 1
- 101001079615 Homo sapiens Heme oxygenase 2 Proteins 0.000 description 1
- 101000596925 Homo sapiens Homeobox protein TGIF1 Proteins 0.000 description 1
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 1
- 101001040800 Homo sapiens Integral membrane protein GPR180 Proteins 0.000 description 1
- 101001003149 Homo sapiens Interleukin-10 receptor subunit beta Proteins 0.000 description 1
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 1
- 101000599056 Homo sapiens Interleukin-6 receptor subunit beta Proteins 0.000 description 1
- 101000945351 Homo sapiens Killer cell immunoglobulin-like receptor 3DL1 Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101100461044 Homo sapiens NSD3 gene Proteins 0.000 description 1
- 101000582320 Homo sapiens Neurogenic differentiation factor 6 Proteins 0.000 description 1
- 101001091194 Homo sapiens Peptidyl-prolyl cis-trans isomerase G Proteins 0.000 description 1
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 101001068027 Homo sapiens Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Proteins 0.000 description 1
- 101001068019 Homo sapiens Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform Proteins 0.000 description 1
- 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 description 1
- 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 description 1
- 101000688930 Homo sapiens Signaling threshold-regulating transmembrane adapter 1 Proteins 0.000 description 1
- 101000740162 Homo sapiens Sodium- and chloride-dependent transporter XTRP3 Proteins 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 101000922131 Homo sapiens Tyrosine-protein kinase CSK Proteins 0.000 description 1
- 101001135589 Homo sapiens Tyrosine-protein phosphatase non-receptor type 22 Proteins 0.000 description 1
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
- 101000926525 Homo sapiens eIF-2-alpha kinase GCN2 Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 101150062179 II gene Proteins 0.000 description 1
- 101150091030 ITM2B gene Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 102100023350 Integral membrane protein 2B Human genes 0.000 description 1
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 description 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
- 102100020788 Interleukin-10 receptor subunit beta Human genes 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102100039897 Interleukin-5 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 102100037795 Interleukin-6 receptor subunit beta Human genes 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000701244 Mastadenovirus Species 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241000711513 Mononegavirales Species 0.000 description 1
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 1
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 1
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100446506 Mus musculus Fgf3 gene Proteins 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000187488 Mycobacterium sp. Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- KTHDTJVBEPMMGL-VKHMYHEASA-N N-acetyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(C)=O KTHDTJVBEPMMGL-VKHMYHEASA-N 0.000 description 1
- KTHDTJVBEPMMGL-UHFFFAOYSA-N N-acetyl-L-alanine Natural products OC(=O)C(C)NC(C)=O KTHDTJVBEPMMGL-UHFFFAOYSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 102100030589 Neurogenic differentiation factor 6 Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 102100024894 PR domain zinc finger protein 1 Human genes 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 108010009975 Positive Regulatory Domain I-Binding Factor 1 Proteins 0.000 description 1
- 102100033762 Proheparin-binding EGF-like growth factor Human genes 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 101710150114 Protein rep Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 241001068295 Replication defective viruses Species 0.000 description 1
- 101710152114 Replication protein Proteins 0.000 description 1
- 241000271569 Rhea Species 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102100034464 Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Human genes 0.000 description 1
- 102100034470 Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform Human genes 0.000 description 1
- 241000620568 Siadenovirus Species 0.000 description 1
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 description 1
- 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 description 1
- 102100024453 Signaling threshold-regulating transmembrane adapter 1 Human genes 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 101000987219 Sus scrofa Pregnancy-associated glycoprotein 1 Proteins 0.000 description 1
- 101001045447 Synechocystis sp. (strain PCC 6803 / Kazusa) Sensor histidine kinase Hik2 Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 1
- 108091007178 TNFRSF10A Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 1
- 102100039094 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 102100031167 Tyrosine-protein kinase CSK Human genes 0.000 description 1
- 102100033138 Tyrosine-protein phosphatase non-receptor type 22 Human genes 0.000 description 1
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 241001115400 Zaire ebolavirus Species 0.000 description 1
- 102100026497 Zinc finger protein 654 Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000011496 cAMP-mediated signaling Effects 0.000 description 1
- 108010018828 cadherin 5 Proteins 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- FFQKYPRQEYGKAF-UHFFFAOYSA-N carbamoyl phosphate Chemical compound NC(=O)OP(O)(O)=O FFQKYPRQEYGKAF-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 102100034175 eIF-2-alpha kinase GCN2 Human genes 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000007674 genetic toxicity Effects 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000019734 interleukin-12 production Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000003039 myelosuppressive effect Effects 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 229940022007 naked DNA vaccine Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009295 sperm incapacitation Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 101150098170 tat gene Proteins 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 229940023147 viral vector vaccine Drugs 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562101968P | 2015-01-09 | 2015-01-09 | |
| US62/101,968 | 2015-01-09 | ||
| PCT/US2016/012482 WO2016112188A1 (en) | 2015-01-09 | 2016-01-07 | Methods and compositions for ebola virus vaccination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20170102002A true KR20170102002A (ko) | 2017-09-06 |
Family
ID=56356425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177022208A Ceased KR20170102002A (ko) | 2015-01-09 | 2016-01-07 | 에볼라 바이러스 백신접종을 위한 방법 및 조성물 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10695417B2 (enExample) |
| EP (1) | EP3256140B1 (enExample) |
| JP (1) | JP2018502922A (enExample) |
| KR (1) | KR20170102002A (enExample) |
| CN (1) | CN107530383A (enExample) |
| AU (1) | AU2016205208A1 (enExample) |
| CA (1) | CA2973109A1 (enExample) |
| ES (1) | ES2795833T3 (enExample) |
| WO (1) | WO2016112188A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2170384T3 (en) | 2007-07-02 | 2016-07-25 | Etubics Corp | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination |
| EP3256140B1 (en) | 2015-01-09 | 2020-04-01 | Etubics Corporation | Compositions for ebola virus vaccination |
| CN109843323B (zh) * | 2016-07-15 | 2022-06-07 | 埃特彼塞斯公司 | 用于黄病毒疫苗接种的组合物和方法 |
| JP6903120B2 (ja) | 2016-07-15 | 2021-07-14 | エトゥビクス コーポレーション | アルファウイルスワクチン接種のための組成物及び方法 |
| WO2018039640A1 (en) * | 2016-08-26 | 2018-03-01 | The Broad Institute, Inc. | Nucleic acid amplification assays for detection of pathogens |
| US20220339283A1 (en) * | 2019-09-10 | 2022-10-27 | The Penn State Research Foundation | Lipopolysaccharide molecules for enhancing immune responses |
| US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
| US12285480B2 (en) | 2020-03-11 | 2025-04-29 | Nantcell, Inc. | Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses |
| EP4118109A1 (en) | 2020-03-11 | 2023-01-18 | NantCell, Inc. | Proteinaceous therapeutics |
| US20210284716A1 (en) * | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
| AU2021236141B2 (en) * | 2020-03-11 | 2024-05-30 | Nantcell, Inc. | Treatment of covid-19 and methods therefor |
| EP4377336A4 (en) | 2021-07-29 | 2025-07-16 | Nantcell Inc | MODIFIED T CELL RECEPTORS FOR THE PREVENTION AND TREATMENT OF VIRAL INFECTIONS AND CANCER |
| EP4335870A1 (en) | 2022-09-06 | 2024-03-13 | NantCell, Inc. | Peptide therapeutics against sars-cov-2 spike protein |
| CN121057589A (zh) * | 2023-05-04 | 2025-12-02 | 免疫生物公司 | 腺病毒载体转导的单采产物 |
| WO2025238195A1 (en) * | 2024-05-16 | 2025-11-20 | Ferring International Center S.A. | Method for the purification of recombinant adenovirus vectors |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| US6045802A (en) | 1994-10-03 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US7118754B1 (en) | 1996-07-30 | 2006-10-10 | Transgene S.A. | Pharmaceutical composition for treating papillomavirus tumors and infection |
| US5994132A (en) | 1996-10-23 | 1999-11-30 | University Of Michigan | Adenovirus vectors |
| US6706693B1 (en) | 1997-08-13 | 2004-03-16 | The Uab Research Foundation | Vaccination by topical application of genetic vectors |
| US6348450B1 (en) | 1997-08-13 | 2002-02-19 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom and uses thereof |
| WO1999008713A1 (en) | 1997-08-13 | 1999-02-25 | The Uab Research Foundation | Vaccination by topical application of genetic vectors |
| US6716823B1 (en) | 1997-08-13 | 2004-04-06 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom, and uses thereof |
| US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| ES2286530T3 (es) | 1997-10-10 | 2007-12-01 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Peptidos antagonistas del antigeno carcinoembrionario (cea). |
| EP1447414B1 (en) | 1997-10-10 | 2007-06-06 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Antagonist peptides of carcinoembryonic antigen (CEA) |
| US6756038B1 (en) | 1997-10-10 | 2004-06-29 | The United States Of America As Represented By The Department Of Health And Human Services | Agonist and antagonist peptides of carcinoembryonic antigen (CEA) |
| US6413513B1 (en) | 1998-05-22 | 2002-07-02 | Entremed, Inc. | Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers |
| US6734172B2 (en) | 1998-11-18 | 2004-05-11 | Pacific Northwest Research Institute | Surface receptor antigen vaccines |
| EP1137792B9 (en) | 1998-12-09 | 2007-12-12 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| US20040009936A1 (en) | 1999-05-03 | 2004-01-15 | Tang De-Chu C. | Vaccine and drug delivery by topical application of vectors and vector extracts |
| US7001995B1 (en) | 1999-08-25 | 2006-02-21 | Merck & Co., Inc. | Synthetic human papillomavirus genes |
| WO2001030382A1 (en) | 1999-10-22 | 2001-05-03 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
| AU2001280674A1 (en) | 2000-07-20 | 2002-02-05 | Genstar Therapeutics Corporation | Mini-adenoviral vector system for vaccination |
| US7083787B2 (en) | 2000-11-15 | 2006-08-01 | Globeimmune, Inc. | Yeast-dendritic cell vaccines and uses thereof |
| WO2003008537A2 (en) | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
| US20040091995A1 (en) | 2001-06-15 | 2004-05-13 | Jeffrey Schlom | Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses |
| JP2004535816A (ja) | 2001-07-20 | 2004-12-02 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｃｉｎを含むｈｐｖ関連の前癌性増殖および癌性増殖に関する方法および組成物 |
| ES2290449T3 (es) | 2002-04-09 | 2008-02-16 | Sanofi Pasteur Limited | Acido nucleico de cea modificado y vectores de expresion. |
| US8236776B2 (en) | 2002-04-09 | 2012-08-07 | Sanofi Pasteur Limited | Modified CEA nucleic acid and expression vectors |
| WO2004110345A2 (en) | 2002-10-29 | 2004-12-23 | Pharmacia Corporation | Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same |
| CN1548537B (zh) | 2002-12-27 | 2010-05-05 | 深圳市源兴生物医药科技有限公司 | 疫苗制备方法和抗肿瘤疫苗 |
| JP2007523610A (ja) | 2003-05-05 | 2007-08-23 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | 癌胎児抗原をコードする合成遺伝子およびその使用 |
| US8207314B2 (en) | 2003-05-16 | 2012-06-26 | Sanofi Pasteur Limited | Tumor antigens for prevention and/or treatment of cancer |
| JP4772674B2 (ja) | 2003-07-21 | 2011-09-14 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ヒト上皮成長因子２／ｎｅｕ抗原をコードする合成遺伝子およびその用途 |
| JP2007535304A (ja) | 2003-11-24 | 2007-12-06 | シドニー キンメル キャンサー センター | ムチン抗原ワクチン |
| CA2548347A1 (en) | 2003-12-11 | 2005-06-30 | Sidney Kimmel Cancer Center | Methods for generating immunity to antigen |
| ES2616337T3 (es) | 2003-12-12 | 2017-06-12 | Government Of The United States Of America, As Repr. By The Secr. Of The Dept. Of Health And Human Services And His Successors | Un epítopo de linfocito T citotóxico humano y su epítopo agonista del número no variable de secuencias de repetición en tándem de MUC-1 |
| CA2555013C (en) | 2004-02-11 | 2013-10-15 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Carcinoembryonic antigen fusions and uses thereof |
| US9592284B2 (en) | 2004-04-28 | 2017-03-14 | The Trustees Of The University Of Pennsylvania | Immunization regimen with E4-deleted adenovirus prime and E1-deleted adenovirus boost |
| KR101131727B1 (ko) | 2004-06-11 | 2012-03-28 | 가톨릭대학교 산학협력단 | ＣＥＡ-특이적인 세포독성 Ｔ세포를 생성하는 재조합 아데노바이러스 ＡｄＶＣＥＡ로 트랜스덕션된 수지상세포, 이를 포함하는 백신 및 약제학적 조성물 |
| AU2005295317B2 (en) | 2004-10-18 | 2011-10-13 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| US20100034840A1 (en) | 2005-07-11 | 2010-02-11 | David Apelian | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
| MX2008009929A (es) | 2006-02-02 | 2008-10-01 | Globeimmune Inc | Vacuna a base de levadura para inducir una respuesta inmune. |
| EP2013229A2 (en) | 2006-04-21 | 2009-01-14 | Transgene S.A. | Hpv-18-based papillomavirus vaccine |
| DK2170384T3 (en) * | 2007-07-02 | 2016-07-25 | Etubics Corp | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination |
| US8728489B2 (en) | 2008-09-19 | 2014-05-20 | Globeimmune, Inc. | Immunotherapy for chronic hepatitis C virus infection |
| WO2010065626A1 (en) | 2008-12-02 | 2010-06-10 | Globeimmune, Inc. | Genotyping tools, methods and kits |
| EP2419126B1 (en) | 2009-04-17 | 2018-01-10 | Globeimmune, Inc. | Combination immunotherapy compositions against cancer and methods |
| US20150182621A1 (en) | 2009-04-28 | 2015-07-02 | The Johns Hopkins University | Compositions and methods for enhancing antigen-specific immune responses |
| JP5913103B2 (ja) | 2009-09-14 | 2016-04-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ | 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法 |
| JP2013522302A (ja) | 2010-03-14 | 2013-06-13 | グローブイミューン，インコーポレイテッド | 酵母系免疫療法を使用した感染症の薬理ゲノミクス及び治療反応性ガイド治療 |
| AU2011226992B2 (en) | 2010-05-10 | 2012-03-22 | Ascend Biopharmaceuticals Pty Ltd | Immunostimulatory and vaccine compositions |
| WO2012019127A2 (en) | 2010-08-05 | 2012-02-09 | The Regents Of The University Of Colorado | Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases |
| ES2528472T3 (es) * | 2011-02-03 | 2015-02-10 | The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services | Vacunas multivalentes para el virus de la rabia y filovirus |
| AP2013007110A0 (en) | 2011-02-12 | 2013-09-30 | Globeimmune Inc | Yeast-based therapeutic for chronic hepatitis B infection |
| BR112013032381B1 (pt) | 2011-06-14 | 2021-01-12 | Globeimmune, Inc. | composições à base de levedura e métodos para o tratamento ou prevenção de infecção pelo vírus da hepatite delta |
| RU2017143985A (ru) | 2011-08-17 | 2019-02-14 | Глоубиммьюн, Инк. | Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения |
| SG10201913795TA (en) | 2012-02-02 | 2020-03-30 | Univ Texas | Adenoviruses expressing heterologous tumor-associated antigens |
| US9605276B2 (en) | 2012-08-24 | 2017-03-28 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| EP2895191B1 (en) | 2012-09-14 | 2019-06-05 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Brachyury protein, adenoviral vectors encoding brachyury protein, and their use |
| WO2014160747A2 (en) | 2013-03-26 | 2014-10-02 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection |
| TWI654200B (zh) | 2013-08-30 | 2019-03-21 | 環球免疫公司 | 治療或預防結核病的組合物及方法 |
| US10350275B2 (en) * | 2013-09-21 | 2019-07-16 | Advantagene, Inc. | Methods of cytotoxic gene therapy to treat tumors |
| CA3205348A1 (en) | 2013-10-23 | 2015-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use |
| EP4070818A3 (en) | 2014-01-06 | 2023-01-11 | The Trustees of the University of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
| WO2015127027A1 (en) | 2014-02-20 | 2015-08-27 | Wayne State University | Her2 antigenic polypeptide compositions, and methods for their use in treatment and prevention of carcinomas |
| KR102409372B1 (ko) | 2014-04-11 | 2022-06-16 | 글로브이뮨 | 효모 면역 요법 및 타입 i 인터페론 감도 |
| EP3160498B1 (en) | 2014-06-30 | 2021-10-06 | Altor BioScience Corporation | Il-15-based molecules and methods of use thereof |
| WO2016007499A1 (en) | 2014-07-07 | 2016-01-14 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| JP6647315B2 (ja) | 2015-01-09 | 2020-02-14 | イーチュービクス コーポレイション | 組み合わせ免疫療法のための方法および組成物 |
| EP3256140B1 (en) | 2015-01-09 | 2020-04-01 | Etubics Corporation | Compositions for ebola virus vaccination |
| EP3286213B1 (en) | 2015-04-20 | 2021-08-04 | Etubics Corporation | Methods and compositions for combination immunotherapy |
-
2016
- 2016-01-07 EP EP16735409.1A patent/EP3256140B1/en active Active
- 2016-01-07 AU AU2016205208A patent/AU2016205208A1/en not_active Abandoned
- 2016-01-07 KR KR1020177022208A patent/KR20170102002A/ko not_active Ceased
- 2016-01-07 CN CN201680014847.2A patent/CN107530383A/zh active Pending
- 2016-01-07 JP JP2017555422A patent/JP2018502922A/ja active Pending
- 2016-01-07 US US15/542,003 patent/US10695417B2/en active Active
- 2016-01-07 WO PCT/US2016/012482 patent/WO2016112188A1/en not_active Ceased
- 2016-01-07 CA CA2973109A patent/CA2973109A1/en not_active Abandoned
- 2016-01-07 ES ES16735409T patent/ES2795833T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2795833T3 (es) | 2020-11-24 |
| CN107530383A (zh) | 2018-01-02 |
| JP2018502922A (ja) | 2018-02-01 |
| WO2016112188A1 (en) | 2016-07-14 |
| EP3256140A4 (en) | 2018-07-18 |
| EP3256140A1 (en) | 2017-12-20 |
| AU2016205208A1 (en) | 2017-07-06 |
| US20170368161A1 (en) | 2017-12-28 |
| US10695417B2 (en) | 2020-06-30 |
| EP3256140B1 (en) | 2020-04-01 |
| CA2973109A1 (en) | 2016-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20170102002A (ko) | 에볼라 바이러스 백신접종을 위한 방법 및 조성물 | |
| AU2019216631B2 (en) | Enhanced adoptive cell therapy | |
| CN113456812B (zh) | 用于联合免疫治疗的方法和组合物 | |
| RU2731342C1 (ru) | Фармацевтическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты) | |
| JP2023123766A (ja) | アルファウイルス新生抗原ベクター | |
| KR101614364B1 (ko) | 유인원 ｅ 아데노바이러스 ｓａｄｖ-39, -25.2, -26, -30, -37, 및 -38 | |
| JP2024073576A (ja) | 改変アデノウイルス | |
| KR20190033483A (ko) | 인간 파필로마바이러스 (hpv)-연관 질환의 치료를 위한 조성물 및 방법 | |
| KR20210013105A (ko) | 공유 항원 | |
| KR20210013589A (ko) | 면역 체크포인트 억제제 공동-발현 벡터 | |
| KR20210090650A (ko) | 알파바이러스 신생항원 벡터 및 인터페론 억제제 | |
| AU2019251356B2 (en) | Oncolytic adenovirus compositions with enhanced replication properties | |
| KR20230046313A (ko) | 다중에피토프 백신 카세트 | |
| KR20100109914A (ko) | 유인원 아과 ｂ 아데노바이러스 ｓａｄｖ-28,27,-29,-32,-33, 및 -35 및 그것의 사용 | |
| KR20180012857A (ko) | 아데노바이러스 폴리뉴클레오티드 및 폴리펩티드 | |
| KR20230015914A (ko) | 캡핑 화합물, 조성물 및 이의 사용 방법 | |
| KR20130138245A (ko) | 종양분해 아데노바이러스 벡터 및 이와 관련된 방법 및 용도 | |
| KR20230079359A (ko) | 아데노바이러스 벡터 및 아데노바이러스 벡터의 사용 방법 | |
| KR20220041844A (ko) | Hiv 항원 및 mhc 복합체 | |
| KR20230006825A (ko) | 전염성 질병 항원 및 백신 | |
| KR20230014694A (ko) | 항원-코딩 카세트 | |
| KR20230175091A (ko) | 60세 이상 및/또는 만성 질환을 가진 대상체에서 중증 급성 호흡기 증후군 바이러스 sars-cov-2에 대한 특이 면역을 유도하기 위한 제제(변형체)의 용도 | |
| RU2744444C1 (ru) | Применение средства для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 для ревакцинации населения (варианты) | |
| RU2829510C2 (ru) | Онколитические аденовирусные композиции с улучшенными репликационными свойствами | |
| KR20230146436A (ko) | 집단의 재접종을 위한 중증 급성 호흡기 증후군 바이러스 sars-cov-2에 대한 특이 면역의 유도를 위한 제제(변형체)의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20170808 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| A302 | Request for accelerated examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200316 Comment text: Request for Examination of Application |
|
| PA0302 | Request for accelerated examination |
Patent event date: 20200316 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20200402 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20200825 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20200402 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |